Cancer-Associated Fibroblasts in a 3D Engineered Tissue Model Induce Tumor-like Matrix Stiffening and EMT Transition.

3D tumor models ECM remodeling EMT bladder cancer cancer-associated fibroblasts cell contractility engineered tumor microenvironment matrix stiffness mechanotransduction

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
05 Aug 2022
Historique:
received: 07 07 2022
revised: 30 07 2022
accepted: 01 08 2022
entrez: 12 8 2022
pubmed: 13 8 2022
medline: 13 8 2022
Statut: epublish

Résumé

A tumor microenvironment is characterized by its altered mechanical properties. However, most models remain unable to faithfully recreate the mechanical properties of a tumor. Engineered models based on the self-assembly method have the potential to better recapitulate the stroma architecture and composition. Here, we used the self-assembly method based on a bladder tissue model to engineer a tumor-like environment. The tissue-engineered tumor models were reconstituted from stroma-derived healthy primary fibroblasts (HFs) induced into cancer-associated fibroblast cells (iCAFs) along with an urothelium overlay. The iCAFs-derived extracellular matrix (ECM) composition was found to be stiffer, with increased ECM deposition and remodeling. The urothelial cells overlaid on the iCAFs-derived ECM were more contractile, as measured by quantitative polarization microscopy, and displayed increased YAP nuclear translocation. We further showed that the proliferation and expression of epithelial-to-mesenchymal transition (EMT) marker in the urothelial cells correlate with the increased stiffness of the iCAFs-derived ECM. Our data showed an increased expression of EMT markers within the urothelium on the iCAFs-derived ECM. Together, our results demonstrate that our tissue-engineered tumor model can achieve stiffness levels comparable to that of a bladder tumor, while triggering a tumor-like response from the urothelium.

Identifiants

pubmed: 35954473
pii: cancers14153810
doi: 10.3390/cancers14153810
pmc: PMC9367573
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : CIHR
ID : 258229
Pays : Canada
Organisme : Fondation de l'Université Laval
ID : N/A
Organisme : Canada Research Chairs
ID : N/A
Organisme : Ferring Canada
ID : N/A

Références

J Cell Biol. 2013 Jun 24;201(7):1069-84
pubmed: 23798731
Proc Natl Acad Sci U S A. 2006 Jul 18;103(29):10889-94
pubmed: 16832052
Cell. 2009 Nov 25;139(5):891-906
pubmed: 19931152
Ann N Y Acad Sci. 2020 Aug;1473(1):48-61
pubmed: 32428277
EMBO J. 2017 Sep 1;36(17):2510-2528
pubmed: 28673931
Nat Cell Biol. 2015 May;17(5):678-88
pubmed: 25893917
Dev Cell. 2019 May 6;49(3):332-346
pubmed: 31063753
Oncotarget. 2016 Dec 13;7(50):82609-82619
pubmed: 27655672
Photochem Photobiol. 2020 Mar;96(2):365-372
pubmed: 31820435
Integr Biol (Camb). 2013 Mar;5(3):606-16
pubmed: 23388698
Mil Med Res. 2018 Feb 26;5(1):7
pubmed: 29502528
Biomed Res Int. 2020 Apr 13;2020:6051210
pubmed: 32352002
Front Pharmacol. 2018 Jan 23;9:6
pubmed: 29410625
Cancers (Basel). 2021 Oct 13;13(20):
pubmed: 34680267
Front Mol Biosci. 2020 Mar 06;7:33
pubmed: 32211418
Cancer Res. 2013 Sep 1;73(17):5336-46
pubmed: 23856251
Sci Rep. 2015 Nov 25;5:17203
pubmed: 26603915
Sci Rep. 2015 Jul 08;5:11924
pubmed: 26152796
Nat Commun. 2016 Feb 15;7:10498
pubmed: 26876920
Organogenesis. 2013 Apr-Jun;9(2):70-5
pubmed: 23811696
Mol Cancer Ther. 2015 Nov;14(11):2665-73
pubmed: 26330548
Nat Cell Biol. 2007 Dec;9(12):1392-400
pubmed: 18037882
Nat Med. 2013 Nov;19(11):1423-37
pubmed: 24202395
N Engl J Med. 2004 Sep 16;351(12):1187-96
pubmed: 15371576
APL Bioeng. 2018 Apr 03;2(3):031901
pubmed: 31069314
Burns. 1993 Apr;19(2):99-104
pubmed: 8471157
Elife. 2014 Mar 11;3:e01308
pubmed: 24618895
Methods Mol Biol. 2009;482:233-56
pubmed: 19089360
Biomaterials. 2017 Nov;145:233-241
pubmed: 28888113
Proc Natl Acad Sci U S A. 2009 Dec 1;106(48):20318-23
pubmed: 19915148
Cancers (Basel). 2019 Jul 24;11(8):
pubmed: 31344830
Biophys J. 2014 Dec 2;107(11):2528-37
pubmed: 25468332
Semin Cell Dev Biol. 2017 Jul;67:141-152
pubmed: 27641825
Micromachines (Basel). 2019 Jun 22;10(6):
pubmed: 31234497
J Magn Reson Imaging. 2016 Feb;43(2):384-90
pubmed: 26149267
BMC Cancer. 2011 Jun 13;11:245
pubmed: 21668992
Tissue Eng Part C Methods. 2014 Nov;20(11):905-15
pubmed: 24576074
Cell Death Dis. 2019 Oct 10;10(10):768
pubmed: 31601778
Cancers (Basel). 2020 May 06;12(5):
pubmed: 32384738
Tissue Eng Part A. 2020 Dec;26(23-24):1272-1282
pubmed: 32434426
Cancers (Basel). 2015 Oct 14;7(4):2054-62
pubmed: 26473929
Proc Natl Acad Sci U S A. 2015 Jul 7;112(27):8314-9
pubmed: 26106154
Acta Biomater. 2021 Sep 15;132:448-460
pubmed: 33766799
Dis Model Mech. 2011 Mar;4(2):165-78
pubmed: 21324931
Br J Cancer. 2020 Sep;123(7):1178-1190
pubmed: 32641866
J Cell Physiol. 2018 Apr;233(4):2993-3003
pubmed: 28618001
J Biophotonics. 2018 Nov;11(11):e201800008
pubmed: 29931742
Nat Protoc. 2017 May;12(5):1077-1088
pubmed: 28448484
Amino Acids. 2017 Mar;49(3):425-439
pubmed: 27562794
Phys Biol. 2013 Dec;10(6):065004
pubmed: 24304905
Elife. 2018 Sep 20;7:
pubmed: 30231971
Biotechnol Adv. 2016 Dec;34(8):1427-1441
pubmed: 27845258
PLoS One. 2016 Mar 08;11(3):e0150247
pubmed: 26954362
Circ Res. 2010 Jul 9;107(1):117-25
pubmed: 20489165
Oncogene. 2011 Mar 24;30(12):1436-48
pubmed: 21057535
J Pathol. 2015 Apr;235(5):773-83
pubmed: 25469981
PLoS One. 2012;7(2):e32572
pubmed: 22389710
J Pediatr Urol. 2011 Jun;7(3):276-82
pubmed: 21527232
Nat Commun. 2020 Oct 9;11(1):5120
pubmed: 33037194
Mol Cancer Res. 2018 Jul;16(7):1196-1204
pubmed: 29636362
Theranostics. 2020 Jul 9;10(19):8494-8512
pubmed: 32754259
Integr Biol (Camb). 2019 May 1;11(5):221-234
pubmed: 31251330
J Biomed Opt. 2017 Apr 1;22(4):46004
pubmed: 28388706
Int J Cancer. 1997 Sep 26;73(1):10-5
pubmed: 9334802
Mol Biol Cell. 2017 Jul 7;28(14):1901-1911
pubmed: 28468976
Am J Physiol. 1967 Dec;213(6):1532-44
pubmed: 6075755
Proc Natl Acad Sci U S A. 2016 Oct 25;113(43):12126-12131
pubmed: 27790998
J Cell Biol. 2017 Nov 6;216(11):3509-3520
pubmed: 28931556
Mol Biol Cell. 2012 Mar;23(5):781-91
pubmed: 22238361
Cancer Res. 2020 Apr 1;80(7):1475-1485
pubmed: 32019869
BMC Cancer. 2019 Feb 11;19(1):137
pubmed: 30744595
BMC Med. 2008 Apr 28;6:11
pubmed: 18442412
Cancer Cell Int. 2020 Dec 22;20(1):599
pubmed: 33353547
Nat Rev Mol Cell Biol. 2011 May;12(5):308-19
pubmed: 21508987
Cancer Cell. 2005 Sep;8(3):241-54
pubmed: 16169468
Stroke. 2009 Jul;40(7):2552-6
pubmed: 19478233
Nat Mater. 2021 Apr;20(4):548-559
pubmed: 33257795
J Tissue Eng Regen Med. 2017 Nov;11(11):3090-3099
pubmed: 28156053
Biomaterials. 2011 Dec;32(35):9308-15
pubmed: 21911252
Front Oncol. 2020 Apr 15;10:397
pubmed: 32351878
Oncol Rep. 2017 Apr;37(4):1971-1979
pubmed: 28260082
Biomaterials. 2012 Jun;33(16):4157-65
pubmed: 22405848
Biomaterials. 2018 Feb;155:124-134
pubmed: 29175081
Integr Biol (Camb). 2013 Aug;5(8):1067-75
pubmed: 23832051
J Hematol Oncol. 2019 Nov 8;12(1):112
pubmed: 31703598
Sci Rep. 2019 Nov 20;9(1):17188
pubmed: 31748579
Am J Physiol Cell Physiol. 2015 Mar 15;308(6):C436-47
pubmed: 25500742
Proc Natl Acad Sci U S A. 2017 Jan 17;114(3):492-497
pubmed: 28034921
Biomaterials. 2010 Nov;31(32):8494-506
pubmed: 20709389
In Vitro Cell Dev Biol Anim. 1999 Jun;35(6):318-26
pubmed: 10476918
Biophys J. 2015 Jun 16;108(12):2783-93
pubmed: 26083918
Acta Biomater. 2013 Jan;9(1):4635-44
pubmed: 22902816
Tissue Eng Part C Methods. 2021 Mar;27(3):152-166
pubmed: 33573474
J Biomech Eng. 2018 Jul 1;140(7):
pubmed: 29560498
Can Urol Assoc J. 2013 Jan-Feb;7(1-2):E4-9
pubmed: 23401738
APL Bioeng. 2018 Sep;2(3):
pubmed: 29911682

Auteurs

Martial Millet (M)

CHU de Québec-Université Laval Research Center (Oncology Division) and Université Laval Cancer Research Center, Quebec City, QC G1R 3S3, Canada.

Enola Bollmann (E)

CHU de Québec-Université Laval Research Center (Oncology Division) and Université Laval Cancer Research Center, Quebec City, QC G1R 3S3, Canada.

Cassandra Ringuette Goulet (C)

CHU de Québec-Université Laval Research Center (Oncology Division) and Université Laval Cancer Research Center, Quebec City, QC G1R 3S3, Canada.
CHU de Québec-Université Laval Research Center (Regenerative Medicine Division), Quebec City, QC G1V 4G2, Canada.
Centre de Recherche en Organogénèse Expérimentale/LOEX, Université Laval, Quebec City, QC G1J 1Z4, Canada.

Geneviève Bernard (G)

CHU de Québec-Université Laval Research Center (Regenerative Medicine Division), Quebec City, QC G1V 4G2, Canada.
Centre de Recherche en Organogénèse Expérimentale/LOEX, Université Laval, Quebec City, QC G1J 1Z4, Canada.

Stéphane Chabaud (S)

CHU de Québec-Université Laval Research Center (Regenerative Medicine Division), Quebec City, QC G1V 4G2, Canada.
Centre de Recherche en Organogénèse Expérimentale/LOEX, Université Laval, Quebec City, QC G1J 1Z4, Canada.

Marc-Étienne Huot (MÉ)

CHU de Québec-Université Laval Research Center (Oncology Division) and Université Laval Cancer Research Center, Quebec City, QC G1R 3S3, Canada.
Department of Molecular Biology, Medical Biochemistry and Pathology, Université Laval, Quebec City, QC G1V 0A6, Canada.

Frédéric Pouliot (F)

CHU de Québec-Université Laval Research Center (Oncology Division) and Université Laval Cancer Research Center, Quebec City, QC G1R 3S3, Canada.
Department of Surgery, Université Laval, Quebec City, QC G1V 0A6, Canada.

Stéphane Bolduc (S)

CHU de Québec-Université Laval Research Center (Regenerative Medicine Division), Quebec City, QC G1V 4G2, Canada.
Centre de Recherche en Organogénèse Expérimentale/LOEX, Université Laval, Quebec City, QC G1J 1Z4, Canada.
Department of Surgery, Université Laval, Quebec City, QC G1V 0A6, Canada.

François Bordeleau (F)

CHU de Québec-Université Laval Research Center (Oncology Division) and Université Laval Cancer Research Center, Quebec City, QC G1R 3S3, Canada.
Centre de Recherche en Organogénèse Expérimentale/LOEX, Université Laval, Quebec City, QC G1J 1Z4, Canada.
Department of Molecular Biology, Medical Biochemistry and Pathology, Université Laval, Quebec City, QC G1V 0A6, Canada.

Classifications MeSH